Seladelpar treatment for primary biliary cirrhosis
Part of Digestive system clinical trials.
This study collects real-life data from patients with primary biliary cirrhosis who are already taking seladelpar, to better understand how the drug works outside of clinical trials. It may help improve future treatment for PBC.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years old or older.
- You have been diagnosed with primary biliary cirrhosis (PBC) by a doctor.
- You are currently being treated with the drug seladelpar.
- You are not pregnant or breastfeeding.
- You have not participated in a clinical trial for seladelpar before.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a medicine called seladelpar for people with primary biliary cholangitis (PBC) and cirrhosis, a form of liver scarring. The goal is to see if it can help improve liver health and reduce symptoms.
This study looks at how well two medicines, ursodiol and seladelpar, work together for people with primary biliary cholangitis (PBC), a liver disease. It may help doctors understand the best way to treat PBC and improve liver health.
This trial tests a combination of two experimental drugs (seladelpar and cilofexor) for people with primary biliary cholangitis (PBC) who have not responded well to standard treatment. The goal is to see if these drugs can improve liver health and reduce symptoms.
This trial tests a drug called seladelpar for people who have developed bile duct damage (ischemic cholangiopathy) after a liver transplant. The drug may help improve liver function and reduce symptoms.
This study tests fenofibrate, a medicine that may help lower liver enzymes in people with primary biliary cholangitis (PBC). It looks at how well the drug works in everyday medical practice.
This trial is testing whether adding fenofibrate to the standard PBC medicine ursodeoxycholic acid helps people with primary biliary cholangitis. It's a real-world study, meaning it looks at how treatments work in everyday practice. You can join only if you have already completed an earlier fenofibrate study.
Hear when a new Primary Bilary Cirrhosis (PBC) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.